These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24913713)

  • 21. Immunoproteasome-selective inhibitors: the future of autoimmune diseases?
    Zhang C; Zhu H; Shao J; He R; Xi J; Zhuang R; Zhang J
    Future Med Chem; 2020 Feb; 12(4):269-272. PubMed ID: 31983229
    [No Abstract]   [Full Text] [Related]  

  • 22. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
    de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
    J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
    Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
    Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
    Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
    Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.
    Wang J; Fang Y; Fan RA; Kirk CJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor.
    Arai Y; Shitama H; Yamagishi M; Ono S; Kashima A; Hiraizumi M; Tsuda N; Katayama K; Tanaka K; Koda Y; Kato S; Sakata K; Nureki O; Miyazaki H
    Bioorg Med Chem; 2024 Jul; 109():117790. PubMed ID: 38906067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
    Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
    Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
    Besse A; Kraus M; Mendez-Lopez M; Maurits E; Overkleeft HS; Driessen C; Besse L
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i.
    Allardyce DJ; Bell CM; Loizidou EZ
    Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoproteasome inhibition and bioactivity of thiasyrbactins.
    Bakas NA; Schultz CR; Yco LP; Roberts CC; Chang CA; Bachmann AS; Pirrung MC
    Bioorg Med Chem; 2018 Jan; 26(2):401-412. PubMed ID: 29269255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunoproteasome: an emerging therapeutic target.
    Lee W; Kim KB
    Curr Top Med Chem; 2011 Dec; 11(23):2923-30. PubMed ID: 21824107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A patent review of immunoproteasome inhibitors.
    Ogorevc E; Schiffrer ES; Sosič I; Gobec S
    Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indolo-phakellins as β5-specific noncovalent proteasome inhibitors.
    Beck P; Lansdell TA; Hewlett NM; Tepe JJ; Groll M
    Angew Chem Int Ed Engl; 2015 Feb; 54(9):2830-3. PubMed ID: 25581903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immunoproteasome as a target in hematologic malignancies.
    Kuhn DJ; Orlowski RZ
    Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunoproteasome in antigen processing and other immunological functions.
    Basler M; Kirk CJ; Groettrup M
    Curr Opin Immunol; 2013 Feb; 25(1):74-80. PubMed ID: 23219269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subunit specific inhibitors of proteasomes and their potential for immunomodulation.
    Kisselev AF; Groettrup M
    Curr Opin Chem Biol; 2014 Dec; 23():16-22. PubMed ID: 25217863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.
    Kato H; El-Desoky AH; Takeishi Y; Nehira T; Angkouw ED; Mangindaan REP; de Voogd NJ; Tsukamoto S
    Bioorg Med Chem Lett; 2019 Jan; 29(1):8-10. PubMed ID: 30455150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Activity Relationship Studies of Antimalarial
    Zhang H; Ginn J; Zhan W; Leung A; Liu YJ; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Michino M; Yukawa T; Chelebieva S; Tumwebaze PK; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Liverton N; Foley M; Meinke PT; Nathan CF; Kirkman LA; Lin G
    J Med Chem; 2023 Jan; 66(2):1484-1508. PubMed ID: 36630286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
    Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
    Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.